Position:Supply/Demand> detail

VG11 inhibits the progress of autoimmune diseases

NO:D2018122853511011 Invite:0

Cooperation Details
Applications

Medical Science

Cooperation Mode

Establishment of a joint R & D center or laboratory

Coordination

Seeking partners

Demand outline

Parameter

Basic Information:

1. General Information of Requester

The Institute of Immunology of PLA is a famous Immunologic Institute in China. We have published lots of papers in Journals including Nature, Immunity, Nat Immunol, Nat Commun, Gut and PLoS Pathogens, et al., Additionally, we also applied over 50 cases of patents till now and some of these patents have been used in Translational Medicine. For example, we have developed peptide drugs that have been used in therapy chronic HBV infection. Based on these successful results, our work have also been supported by lots of grants from China including “973” , “863” projects and NSFC projects.

2. International Cooperation Status

 We have cooperated and successfully applied a NSFC-NIH grant. Additionally, we also published over 5 papers in journals with co-authors.

Technical Requirements Summary:

1. Importance and necessity of requested project, and relations with key projects and industries of Chongqing .

In the coming days, both of us would continue to focus on how VG11 can inhibit the progress of autoimmune diseases. These are including:

1)        How to product high quantitative and qualitative of VG11;

2)        Apply and get an international patent;

3)        Apply the VG11 to therapy some patients who suffered from autoimmune diseases, like MS, RA and SLE;

4)        How VG11 attenuates the pathogenesis of disease and the signaling pathways.

Our cooperation would promote the progress of BioMedicne industries of Chongqing.

1.    Technology breakthroughs and innovations of requested project

How to product high quantitative and qualitative of VG11;

1)        How VG11 attenuates the pathogenesis of disease and the signaling pathways;

Clarify the molecular structure of VG11 and its ligands.


Demand side

Company

中匈技术转移中心

Field

Income

Experience

Cooperation

Introduction

中国-匈牙利技术转移中心(重庆)于2016年11月4日签署成立宣言,2017年5月16日“中国-匈牙利技术转移中心”(重庆办公室)正式揭牌。2017年11月30日,“中国-匈牙利技术转移中心”(布达佩斯办公室)正式揭牌。中方运营机构为重庆市科学技术局和重庆市科学技术研究院指导下的重庆高技术创业中心,匈方运营机构为国家贸易署和国家创新署下属宝依·佐尔坦应用研究非盈利责任公司。中匈技术转移中心(重庆)是通过“政府搭建平台,专业机构服务”的工作模式”,分设重庆办公室和匈牙利办公室来推动两地科技人才、技术、资本和产业化转移转化的一种点对面的技术转移模式。秉持“共商、共建、共享”原则,广泛联合中匈双方政界、学界、商界、科技界,以“互联网+”的理念构建覆盖整个区域的中匈技术转移协作网络,凝聚和培养专业化的技术转移机构和人才队伍,搭建高效务实的综合性跨国技术转移信息服务平台,深入挖掘中匈双方国家的战略发展需求,为中匈企业及相关机构间开展成果转移转化等提供专业化配套服务。

  • Apply
  • Favorite

Other information

Address:重庆市渝北区黄山大道中段杨柳路2号B塔楼4层